Caplin Point Gets USFDA Nod

  Published 10 months ago

Caplin Point received USFDA approval for generic Milrinone injection, targeting acute decompensated heart failure treatment.

  • Approval covers two Milrinone infusion dosage forms, ensuring availability in safe, effective single-dose infusion bag packaging.
  • Milrinone Lactate Injection recorded $11 million in US sales for the 12 months ending July 2025.
  • Caplin Point expands presence in regulated US markets via subsidiaries Caplin Steriles and Caplin Steriles USA Inc.

You might like these

Aurionpro Q1 Grows, Stock Falls

KEC Wins Rs 7,000 Cr Worth of Orders

Euro Zone Bonds Fall on Inflation, US Tariff Concerns

Oil Dip Boosts Rupee-Weak Dollar Outlook

L&T Wins Major Orders Across Units

Infosys BPM Launches AI-Powered Invoice Processing

Delta Air Lines: India Return & No Indigo Investment

News that matters the most ⚡